Q-omics provides the consensus-scored CD19 profile across patient tissues and cancer cell-line models. CD19 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CD19 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, CD19 RNA expression shows 16,381 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where CD19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD19 survival associations across molecular data types. CD19 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD19 RNA expression–survival associations across cancer types. High CD19 expression shows unfavorable associations in LGG, but favorable associations in HNSC, LUAD, SKCM, ESCA and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CD19 RNA expression.
This table summarizes CD19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CD19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD19 shows lower tumor expression in COAD, KICH and THCA and higher tumor expression in LUAD, BRCA and KIRC. The COAD box plot shows higher CD19 RNA expression in normal versus tumor tissue (log2 FC = −1.110, t-test p < 0.001).
This table shows molecular features associated with CD19 in patient tissues and cancer cell lines. In patient samples, CD19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
